Mittie Doyle Sells 1,000 Shares of Avalo Therapeutics (NASDAQ:AVTX) Stock

Avalo Therapeutics, Inc. (NASDAQ:AVTX) insider Mittie Doyle sold 1,000 shares of Avalo Therapeutics stock in a transaction dated Monday, July 27th. The shares were sold at an average price of $20.00, for a total transaction of $20,000.00. Following the sale, the insider directly owned 51,776 shares in the company, valued at $1,035,520. The trade was a 1.89% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mittie Doyle also recently made the following trade(s):

• On Tuesday, June 23rd, Mittie Doyle sold 1,450 shares of Avalo Therapeutics stock. The shares were sold at an average price of $18.00, for a total transaction of $26,100.00.

Avalo Therapeutics Price Performance

AVTX stock opened at $19.39 on Friday. Avalo Therapeutics, Inc. has a 1 year low of $6.57 and a 1 year high of $24.27. The firm has a 50-day moving average of $16.98 and a 200 day moving average of $16.19. The company has a market cap of $1.03 billion, a P/E ratio of -3.55 and a beta of 0.78.

Avalo Therapeutics (NASDAQ:AVTX) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.02. On average, equities research analysts expect that Avalo Therapeutics, Inc. will post -2.58 earnings per share for the current fiscal year.

Institutional Trading of Avalo Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. UBS Group AG increased its position in Avalo Therapeutics by 956.9% during the 4th quarter. UBS Group AG now owns 477,816 shares of the company’s stock valued at $8,677,000 after buying an additional 432,608 shares in the last quarter. Moody Aldrich Partners LLC bought a new stake in Avalo Therapeutics in the fourth quarter worth $2,419,000. Nan Fung Trinity HK Ltd. bought a new stake in Avalo Therapeutics in the fourth quarter worth $3,432,000. Jennison Associates LLC purchased a new stake in shares of Avalo Therapeutics in the fourth quarter worth $8,637,000. Finally, Affinity Asset Advisors LLC grew its stake in shares of Avalo Therapeutics by 27.6% in the first quarter. Affinity Asset Advisors LLC now owns 1,340,840 shares of the company’s stock worth $20,019,000 after acquiring an additional 289,786 shares during the last quarter. 87.06% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on AVTX shares. HC Wainwright dropped their price target on Avalo Therapeutics from $40.00 to $35.00 and set a “buy” rating on the stock in a research report on Thursday, May 14th. BTIG Research reiterated a “buy” rating and issued a $58.00 price objective on shares of Avalo Therapeutics in a report on Tuesday, June 16th. Cantor Fitzgerald reissued an “overweight” rating on shares of Avalo Therapeutics in a research report on Friday, July 24th. Citigroup restated an “outperform” rating on shares of Avalo Therapeutics in a report on Wednesday, May 6th. Finally, Mizuho upped their target price on shares of Avalo Therapeutics from $39.00 to $45.00 and gave the stock an “outperform” rating in a research report on Thursday, May 14th. Thirteen equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $45.80.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.